What is Axogen?
Founded in 2002, AxoGen specializes in the development and production of advanced surgical solutions for peripheral nerve injuries. The company's core competency lies in its comprehensive product suite, which includes the Avance Nerve Graft, AxoGuard Nerve Connector, and AxoGuard Nerve Protector. These technologies are engineered to facilitate effective nerve repair and regeneration, addressing critical needs in hospitals, surgery centers, and military medical facilities. Beyond its surgical portfolio, AxoGen provides essential diagnostic tools such as the AcroVal neurosensory testing system and AxoTouch discriminator, positioning itself as a holistic provider in the neuro-regenerative space. The company's market position is defined by its focus on tensionless nerve repair and its ability to serve a diverse range of clinical environments globally.
How much funding has Axogen raised?
Axogen has raised a total of $99.3M across 8 funding rounds:
Series B
$7.8M
Series C
$12.1M
Debt
$2.6M
Debt
$3.7M
Debt
$3M
Stock Offering
$18M
Share Placement
$17.1M
Debt
$35M
Series B (2006): $7.8M with participation from Springboard Capital
Series C (2007): $12.1M led by DeNovo Ventures, Accuitive Medical Ventures, Cardinal Partners, and Springboard Capital II
Debt (2009): $2.6M, investors not publicly disclosed
Debt (2011): $3.7M, investors not publicly disclosed
Debt (2011): $3M, investors not publicly disclosed
Stock Issuance/Offering (2013): $18M, investors not publicly disclosed
Share Placement (2015): $17.1M led by Essex Woodlands
Debt (2020): $35M supported by Oberland Capital Management LLC
Key Investors in Axogen
Essex Woodlands
EW Healthcare Partners is a healthcare growth equity firm that invests in companies across the US and Europe, focusing on driving positive change in healthcare while achieving high returns.
Accuitive Medical Ventures
Accuitive Medical Ventures is a venture capital firm specializing in revolutionary medical device technology investment opportunities and management of technologies developed within The Innovation Factory.
Cardinal Partners
Cardinal Partners is a leading venture capital partnership focused exclusively on healthcare investing, specializing in early-stage financing rounds for growth companies.
What's next for Axogen?
Looking ahead, AxoGen is well-positioned to leverage its recent capital influx to accelerate research and development initiatives and expand its commercial reach. The strategic deployment of these funds will likely focus on enhancing the clinical adoption of its nerve repair portfolio and potentially exploring new diagnostic applications. As the company matures, the focus will shift toward sustaining its competitive advantage in the MedTech landscape, driven by high-barrier-to-entry innovations and a proven track record of clinical efficacy. Investors and stakeholders can expect continued emphasis on operational excellence and market penetration, as AxoGen seeks to solidify its role as the standard-bearer for peripheral nerve regeneration solutions.
See full Axogen company page
